Volume 21, Number 9—September 2015
THEME ISSUE
Emerging Infections Program
Emerging Infections Program
Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012
Table
Selected characteristics among women with a diagnosis of CIN2+, Emerging Infections Program HPV-IMPACT project, United States, 2008–2012*
Characteristic | No. (%) |
---|---|
Diagnosis age, y, N = 13,089 | |
18–20 | 507 (4) |
21–29 | 6,294 (48) |
30–39 | 3,774 (29) |
40–49 | 1,575 (12) |
>50 |
939 (7) |
Race/ethnicity, N = 10,932 | |
White, non-Hispanic | 6,629 (61) |
Black, non-Hispanic | 1,857 (17) |
Hispanic | 1,540 (14) |
Asian | 551 (5) |
Other | 355 (3) |
Missing |
2,157 |
Vaccination status, N = 7,344 | |
Vaccinated | 1,811 (25) |
Not vaccinated | 1,812 (25) |
Unknown | 3,721 (51) |
Not age-eligible |
5,745 |
Diagnosis, N = 13,089 | |
CIN2 | 6,275 (48) |
CIN2/3 | 2,149 (16) |
CIN3/AIS |
4,665 (36) |
Site location, N = 13,089 | |
California | 2,286 (17) |
Connecticut | 3,729 (28) |
New York | 2,813 (21) |
Oregon | 2,557 (20) |
Tennessee | 1,704 (13) |
*AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; CIN+, CIN grade 2 or 3 or adenocarcinoma in situ; HPV, human papillomavirus.
1Members of the Working Group are Ashley Williamson, Manideepthi Pemmaraju, Robert S. Laing III, Deven Patel, and Kyle Higgins.
Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.